Alligator Bioscience: First Patient Dosed With ATOR-1017 Developed for Metastasized Cancer

LUND, Sweden, Dec. 17, 2019 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized…

No Comments

No comments yet.

Sorry, the comment form is closed at this time.